- Home
- MUFG vs VRTX Comparison
MUFG vs VRTX Comparison
Compare MUFG & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUFG
- VRTX
- Stock Information
- Founded
- MUFG 1880
- VRTX 1989
- Country
- MUFG Japan
- VRTX United States
- Employees
- MUFG N/A
- VRTX N/A
- Industry
- MUFG Commercial Banks
- VRTX EDP Services
- Sector
- MUFG Finance
- VRTX Technology
- Exchange
- MUFG Nasdaq
- VRTX Nasdaq
- Market Cap
- MUFG 141.2B
- VRTX 115.6B
- IPO Year
- MUFG 2001
- VRTX 1991
- Fundamental
- Price
- MUFG $13.64
- VRTX $472.35
- Analyst Decision
- MUFG
- VRTX Buy
- Analyst Count
- MUFG 0
- VRTX 25
- Target Price
- MUFG N/A
- VRTX $509.00
- AVG Volume (30 Days)
- MUFG 3.7M
- VRTX 1.2M
- Earning Date
- MUFG 07-31-2025
- VRTX 08-04-2025
- Dividend Yield
- MUFG 2.57%
- VRTX N/A
- EPS Growth
- MUFG N/A
- VRTX N/A
- EPS
- MUFG 0.72
- VRTX N/A
- Revenue
- MUFG $36,975,067,465.00
- VRTX $11,099,700,000.00
- Revenue This Year
- MUFG $11.01
- VRTX $10.43
- Revenue Next Year
- MUFG $16.96
- VRTX $10.81
- P/E Ratio
- MUFG $18.27
- VRTX N/A
- Revenue Growth
- MUFG 5.64
- VRTX 8.98
- 52 Week Low
- MUFG $8.75
- VRTX $377.85
- 52 Week High
- MUFG $15.03
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- MUFG 50.47
- VRTX 60.84
- Support Level
- MUFG $13.52
- VRTX $455.79
- Resistance Level
- MUFG $13.70
- VRTX $484.56
- Average True Range (ATR)
- MUFG 0.14
- VRTX 8.86
- MACD
- MUFG -0.03
- VRTX 2.97
- Stochastic Oscillator
- MUFG 36.27
- VRTX 73.06
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.